US02008G1022
© BusinessWire
03.02.2026
ALUR
LISTED
NYSE
Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a partnership with Bionut, a leader in obesity care in Argentina, and Farmastar, a local pharmacy partner with access to the official supplier of Mounjaro (tirzepatide) in Argentina, to provide patients with access to discounted Mounjaro to be...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
ALUR
LISTED
NYSE
Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced preliminary, unaudited results for the fourth quarter and full year 2025. Management expects preliminary, unaudited results for the period as follows:
Fourth quarter revenue of $3.3 million to $3.7 million, a 22% to 37% increase quarter-ove...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2025
ALUR
LISTED
NYSE
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence.
76 patients treated with the Allurion Smart Capsule were started on low-do...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
20.11.2025
ALUR
LISTED
NYSE
New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of a peer-reviewed, case-controlled study on the use of the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone and its impact on weight loss and body composition.
Published in...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© BusinessWire
18.11.2025
ALUR
LISTED
NYSE
Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with ProSurg Medical, a leading Brazilian medical device company specializing in bariatric and obesity care. This new partnership draws upon ProSurg Medical’s 30-year experience in the Brazilian market and...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ALUR
LISTED
NYSE
Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the third quarter and provided a business update.
Recent Company Highlights
Successfully passed U.S. Food and Drug Administration (“FDA”) Pre-Approval Inspection and Bioresearch Monitoring (BIMO) audit with zero...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2025
ALUR
LISTED
NYSE
Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing
News Preview
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a pioneer in metabolically healthy weight loss, today announced it has passed critical milestones in the U.S. Food and Drug Administration (the “FDA”) Pre-Market Approval (“PMA”) process for the Allurion Smart Capsule.
In addition, the Company announced it has entered into a...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ALUR
LISTED
NYSE
Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the third quarter 2025 on Wednesday, November 12, 2025. Company management will host a conference call to discuss financial results and provide a business update on the sa...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ALUR
LISTED
NYSE
Allurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight Loss
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of the first peer-reviewed study on the consecutive use of the Allurion Smart Capsule, a first of its kind, swallowable, procedure-less weight-loss device.
Published in Obesity Surgery, a leading international journal dedicat...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
ALUR
LISTED
NYSE
Allurion to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference, which will be held on October 9, 2025 at the Metropolitan Club in New York City. Management will hold one-on-one meetings with investors throughout the day.
Invest...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2025
ALUR
LISTED
NYSE
Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update.
Recent Company Highlights and Outlook
Announced new strategic direction focused on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market e...
Themefolio
Profiler
Peergroup
© BusinessWire
22.07.2025
ALUR
LISTED
NYSE
Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced new publications on long-term weight loss results with the Allurion Program.
In the first study, 522 patients treated with the Allurion Program across nine international obesity centers reduced their weight, on average, by 14.4kg (32lbs) or...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
09.07.2025
ALUR
LISTED
NYSE
Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with Minogue Medical Inc., a leading Canadian medical device company specializing in bariatric and obesity care. This new partnership draws upon Minogue Medical’s 40-year experience in the Canadian market a...
Themefolio
Profiler
Peergroup
© BusinessWire
07.07.2025
ALUR
LISTED
NYSE
Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced submission of the fourth and final module of the Pre-Market Approval (PMA) application to the Food & Drug Administration (FDA) and additional, supportive analyses from the AUDACITY Study that meet both of the pre-specified co-primary endpo...
Themefolio
Profiler
Peergroup
© BusinessWire
17.06.2025
ALUR
LISTED
NYSE
Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today presented two new abstracts at the American Society for Metabolic & Bariatric Surgery (ASMBS) 2025 Annual Meeting.
This data include findings from a global, real-world experience evaluating body composition outcomes that demonstrate sustained weig...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
ALUR
LISTED
NYSE
Allurion to Present at Jefferies Global Healthcare Conference
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation will take place on Wednesday, June 4 at 3:45 p.m....
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
ALUR
LISTED
NYSE
Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the presentation of a study at the Societe Francaise et Francophone de Chiurgie de l’Obesite et des Maladies Metaboliques (SOFFCO.MM) meeting in Saint-Etienne, France, May 22-23, 2025.
The study, entitled “The S...
Themefolio
Profiler
Peergroup
© BusinessWire
14.05.2025
ALUR
LISTED
NYSE
Allurion Reports First Quarter 2025 Financial Results and Provides Business Update
News Preview
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update.
Recent Company Highlights and Outlook
Maintaining 2025 revenue guidance of approximately $30 million with a reduction of approximately...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
ALUR
LISTED
NYSE
Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the presentation of four abstracts at the European Congress on Obesity (ECO) taking place in Malaga, Spain, May 11-14, 2025. These studies highlight the transformative impact of the Allurion Balloon and the Virtua...
Themefolio
Profiler
Peergroup
© BusinessWire
05.05.2025
ALUR
LISTED
NYSE
Allurion to Report First Quarter 2025 Financial Results on May 14, 2025
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the first quarter 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
ALUR
LISTED
NYSE
Allurion Announces Postponement of Special Meeting of Stockholders
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that its Special Meeting of Stockholders (the “Special Meeting”), originally scheduled for Friday, April 4, 2025, has been postponed. The Special Meeting is now scheduled to be held on Thursday, April 10, 2025 at 12:00 p.m...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
ALUR
LISTED
NYSE
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
News Preview
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.
Recent Company Highlights and Outlook
Reported initial data on the combination of the Allurion Program w...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
ALUR
LISTED
NYSE
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence.
52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after co...
Themefolio
Profiler
Peergroup
© BusinessWire
12.03.2025
ALUR
LISTED
NYSE
Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the fourth quarter 2024 on Wednesday, March 26, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
ALUR
LISTED
NYSE
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) dated February 19, 2025 for U.S. Patent No. 12,246,163 titled “Automatic-Sealing Balloon-Filling Catheter System” and U.S. Pate...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
ALUR
LISTED
NYSE
Allurion to Participate in Upcoming Investor Conferences
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences.
Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at 9:10 a.m. ET and host one-on-one investor meetings throughout the day on March 3...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
ALUR
LISTED
NYSE
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 900,000 shares of the Company’s common stock at a price of $5.23 per share and warrants to pu...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
ALUR
LISTED
NYSE
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 900,000 shares of the Company’s common stock at a price of $5.23 per share in a register...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
ALUR
LISTED
NYSE
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 agonists. The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrati...
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
ALUR
LISTED
NYSE
Allurion Relaunches in France
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, cleared Allurion to resume sales.
“We are thrilled the Allurion Balloon will once again serve French patients as a clinic...
Themefolio
Profiler
Peergroup
© BusinessWire
24.01.2025
ALUR
LISTED
NYSE
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,240,000 shares of the Company’s common stock at a price of $6.00 per share in a regist...
Themefolio
Profiler
Peergroup
© BusinessWire
23.01.2025
ALUR
LISTED
NYSE
Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition.
Previous studies in patients undergoing GLP-1 therapy have de...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
ALUR
LISTED
NYSE
Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) dated January 15, 2025 for U.S. Patent No. 12,209,677 titled “Binary Fluid Control Valve System”. This patent covers additional c...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2025
ALUR
LISTED
NYSE
Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024
News Preview
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Investments, LP (“RTW”) for the purchase and sale of 841,751 shares of the Company’s common stock in a private placement at a purchase price...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2025
ALUR
LISTED
NYSE
Allurion Announces Positive Topline Results From AUDACITY Trial
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) pivotal trial evaluating the safety and efficacy of the Allurion Balloon.
The AUDACITY trial is an open-label, multicenter, randomized, controlled study and is the first FDA pivot...
Themefolio
Profiler
Peergroup
© BusinessWire
24.12.2024
ALUR
LISTED
NYSE
Allurion Technologies, Inc. Announces Reverse Stock Split
News Preview
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).
The reverse stock split will take effect at...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
ALUR
LISTED
NYSE
Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it received an Acceptance Letter from the Listings Operations Committee of the New York Stock Exchange (the “NYSE”) stating that the NYSE has accepted the Company’s previously submitted plan to regain compliance with the NYSE’s continued listing s...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2024
ALUR
LISTED
NYSE
Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the launch of AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss medications with the company’s AI-native platform, featuring Coach Iris, to promote long-term weight maintenance, virtual access to dieticians...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
ALUR
LISTED
NYSE
Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update
News Preview
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024 and provided a business update.
Recent Company Highlights
Revenue of $5.4 million, which includes a reduction of $1.2 million for product recalled f...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
ALUR
LISTED
NYSE
Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the presentation of two abstracts at Obesity Week 2024, the annual meeting of The Obesity Society.
The first abstract comprises outcomes data from Allurion’s largest real-world cohort on record. The data, gathered from 19,428 patients across 72 countr...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
ALUR
LISTED
NYSE
Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024
News Preview
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
ALUR
LISTED
NYSE
Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the submission of the first three modules of its premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for the Allurion Balloon. The Company expects to file the fourth and final module of the PMA containing the clinical da...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
ALUR
LISTED
NYSE
Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study in the journal Clinical Obesity on the impact of the Allurion Program on weight reduction and body composition.
The study evaluated weight loss and body composition changes for 167 patients with an average body mass index (B...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2024
ALUR
LISTED
NYSE
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a systematic review and meta-analysis evaluating the effectiveness and safety of the Allurion Program. The analysis reviewed studies conducted between 2016 and 2024 and included data from 11 observational studies comprising a total o...
Themefolio
Profiler
Peergroup
© BusinessWire
05.09.2024
ALUR
LISTED
NYSE
Allurion Receives Continued Listing Standards Notice from NYSE
News Preview
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the NYSE’s continued listing standards because the average market capitalization of the Company...
Themefolio
Profiler
Peergroup
© BusinessWire
05.09.2024
ALUR
LISTED
NYSE
Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study on the safety and effectiveness of the Allurion Program in adolescents.
In the study, 91 adolescents between 15 and 17 years-old with average body mass index (BMI) of 35.6 received the Allurion Balloon and the Allurion Prog...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2024
ALUR
LISTED
NYSE
Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024.
"We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
ALUR
LISTED
NYSE
Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average weight reduction of 10.5% at four months on the Allurion Program, improving to 13.7% at one year. This data indicate that weight loss can not only be maintained by utilizing the Allurion Program, but...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2024
ALUR
LISTED
NYSE
Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial
News Preview
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company’s international commercial sales and operations functions.
"We are thrilled to welcome Adrian to Allurion...
Themefolio
Profiler
Peergroup
© BusinessWire
15.08.2024
ALUR
LISTED
NYSE
Allurion Receives Continued Listing Standards Notice from NYSE
News Preview
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the NYSE’s continued listing standards because the average closing price of the Company’s commo...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2024
ALUR
LISTED
NYSE
Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update
News Preview
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the second quarter ended June 30, 2024 and provided a business update.
Recent Company Highlights
Second quarter revenue of $11.8 million, a sequential increase of $2.4 million or 25% from the...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
